Once a candidate target has been identified, the next step is to
develop a therapy that affects the target in a way that interferes with
its ability to promote cancer cell growth or survival. For example, a targeted therapy could reduce the activity of the target or prevent it from binding to a receptor that it normally activates, among other possible mechanisms.
Most targeted therapies are either small molecules or monoclonal antibodies. Small-molecule compounds
are typically developed for targets that are located inside the cell
because such agents are able to enter cells relatively easily.
Monoclonal antibodies are relatively large and generally cannot enter
cells, so they are used only for targets that are outside cells or on
the cell surface.
Candidate small molecules are usually identified
in what are known as "high-throughput screens," in which the effects of
thousands of test compounds on a specific target protein are examined.
Compounds that affect the target (sometimes called "lead compounds")
are then chemically modified to produce numerous closely related
versions of the lead compound. These related compounds are then tested
to determine which are most effective and have the fewest effects on
nontarget molecules.
Monoclonal antibodies are developed by
injecting animals (usually mice) with purified target proteins, causing
the animals to make many different types of antibodies
against the target. These antibodies are then tested to find the ones
that bind best to the target without binding to nontarget proteins.
Before monoclonal antibodies are used in humans, they are "humanized"
by replacing as much of the mouse antibody molecule as possible with
corresponding portions of human antibodies. Humanizing is necessary to
prevent the human immune system from recognizing the monoclonal antibody
as "foreign"
and destroying it before it has a chance to bind to its target protein.
Humanization is not an issue for small-molecule compounds because they
are not typically recognized by the body as foreign.
This site is for information on the various Chemo treatments and Stem Cell Therapies since 1992. This journey became bitter sweet in 2014, with the passing of my beautiful and dear wife. Sherry, had fought Non - Hodgkins Lymphoma(NHL) since 1990, in and out of remissions time and time again. From T-Cell therapies(1990's) to Dual Cord Blood Transplant(2014), she was in Clinical Trials over the years. This site is for informational purpose only and is not to promote the use of certain therapies.
No comments:
Post a Comment